ClinicalTrials.gg
CompletedNCT04617275Updated Dec 8, 2022Results posted

A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY

A Phase 2 interventional study of PF-06882961 and Placebo in Diabetes and Obesity, sponsored by Pfizer. Completed at 38 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-08.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Diabetes Mellitus by Pfizer — 2 open to participants now, 3 under way, 3 of them phase 3. Diabetes Mellitus · Pfizer.

Enrollment
17th of 30
151 · median 182
Started
2021
the only one that year
Phase 2
7 of 35
none open now
Registered
31st of 35
by date

Among the 35 studies in Diabetes Mellitus by Pfizer, this one is the 17th largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 2, and was the 31st registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 35 studies in Diabetes Mellitus by Pfizer are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Diabetes Mellitus by Pfizer, or all of them as a file.
02

Study summary

This study will assess tolerability, safety, and pharmacodynamics (PD) of twice daily (BID) administration of PF- 06882961 in adult participants with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin and in non-diabetic adults with obesity

03

Conditions studied

  • Diabetes
  • Obesity
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants between the ages of 18 and 75 years, inclusive, at Visit 1 (screening).

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes.
  • History of myocardial infarction, unstable angina, arterial revascularization, stroke, Functional Class II IV heart failure, or within 6 months of screening (Visit 1).
  • Participants with a known medical history of active liver disease (other than non alcoholic hepatic steatosis), including chronic active or C, or primary biliary cirrhosis.
  • History of major depressive disorder or history of other severe psychiatric disorders (eg, schizophrenia or bipolar disorder) within the last 2 years.
  • Any lifetime history of a suicide attempt.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Arm 1-PF-06882961 starting dose of 5 milligram (mg) BID titrated to 120 mg in participants with T2DM

    The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 120 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID

    Drug: PF-06882961

  • Experimental
    Arm 2-PF-06882961 starting dose of 10 mg BID titrated to 100 mg in participants with T2DM

    The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 120 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID

    Drug: PF-06882961

  • Experimental
    Arm 3-PF-06882961 starting dose of 5 mg BID titrated to 80 mg in participants with T2DM

    The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 80 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID

    Drug: PF-06882961

  • Experimental
    Arm 4-PF-06882961 starting dose of 10 mg BID titrated to 80 mg in participants with T2DM

    The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 80 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID

    Drug: PF-06882961

  • Placebo comparator
    Arm 5 - Placebo in subjects with T2DM and Obesity

    Matching Placebo tablets taken twice a day (BID)

    Other: Placebo

  • Experimental
    Arm 6-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with T2DM

    The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID

    Drug: PF-06882961

  • Experimental
    Arm 7-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with Obesity

    The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID

    Drug: PF-06882961

Interventions

  • PF-68882961 will be provided as tablets twice a day (BID)

  • OtherPlacebo

    Placebo comparator will be provided as tablets twice daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity

    An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment. AEs presented below were TEAEs. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE. Assessments of AE intensity were defined as mild (easily tolerated, causing minimal discomfort and not interfering with daily activities), moderate (causing sufficient discomfort and interferes with normal daily activities) and severe (preventing normal daily activities).

    Time frame: Baseline through follow-up (Day 112)

Secondary outcomes

  1. Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

    Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion.

    Time frame: Baseline through Visit 10 (Day 91)

  2. Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria

    Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP \>=30 mmHg; 5) change from baseline (increase or decrease) in supine DBP \>=20 mmHg.

    Time frame: Baseline through Visit 10 (Day 91)

  3. Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria

    ECG assessments included pulse rate (PR), QT, heart rate, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300 msec, or baseline (BL) \>200 msec and \>=25% increase from BL, or BL \<=200 msec and \>=50% increase from BL; QRS interval value \>= 140msec, or \>=50% increase from BL; QTcF value \>450 and \<=480 msec, or \>480 and \<=500 msec, or \>500 msec, or increase from BL\>30 and \<=60 msec, or \>60msec.

    Time frame: Baseline through Visit 10 (Day 91)

  4. Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. Participants who responded "yes" to the questions will be counted. Data relevant to the assessment of suicidality were mapped to the Columbia-Classification Algorithm of Suicide Assessment (C-CASA) codes.

    Time frame: Week 0, 2, 4, 6, 8, 10, 12, 13-14

  5. Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9)

    The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The PHQ-9 were completed by participants and reviewed by site staff at the pre-defined time points.

    Time frame: Week 0, 2, 4, 6, 8, 10, 12, 13-14.

  6. Change From Baseline (CFB) in Fasting Plasma Glucose at Week 2

    Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

    Time frame: Baseline, Week 2

  7. CFB in Fasting Plasma Glucose at Week 4

    Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

    Time frame: Baseline, Week 4

  8. CFB in Fasting Plasma Glucose at Week 6

    Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

    Time frame: Baseline, Week 6

  9. CFB in Fasting Plasma Glucose at Week 8

    Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

    Time frame: Baseline, Week 8

  10. CFB in Fasting Plasma Glucose at Week 10

    Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

    Time frame: Baseline, Week 10

  11. CFB in Fasting Plasma Glucose at Week 12

    Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

    Time frame: Baseline, Week 12

  12. CFB in Glycolated Hemoglobin A1c (HbA1c) at Week 2

    Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

    Time frame: Baseline, Week 2

  13. CFB in Glycolated HbA1c at Week 4

    Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

    Time frame: Baseline, Week 4

  14. CFB in Glycolated HbA1c at Week 6

    Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

    Time frame: Baseline, Week 6

  15. CFB in Glycolated HbA1c at Week 8

    Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

    Time frame: Baseline, Week 8

  16. CFB in Glycolated HbA1c at Week 10

    Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

    Time frame: Baseline, Week 10

  17. CFB in Glycolated HbA1c at Week 12

    Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

    Time frame: Baseline, Week 12

  18. CFB in Body Weight at Week 2 (Participants With T2DM)

    Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.

    Time frame: Baseline, Week 2

  19. CFB in Body Weight at Week 4 (Participants With T2DM)

    Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.

    Time frame: Baseline, Week 4

  20. CFB in Body Weight at Week 6 (Participants With T2DM)

    Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.

    Time frame: Baseline, Week 6

  21. CFB in Body Weight at Week 8 (Participants With T2DM)

    Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.

    Time frame: Baseline, Week 8

  22. CFB in Body Weight at Week 10 (Participants With T2DM)

    Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.

    Time frame: Baseline, Week 10

  23. CFB in Body Weight at Week 12 (Participants With T2DM)

    Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.

    Time frame: Baseline, Week 12

  24. CFB in Body Weight at Week 2 (Non-diabetic Participants With Obesity)

    Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.

    Time frame: Baseline, Week 2

  25. CFB in Body Weight at Week 4 (Non-diabetic Participants With Obesity)

    Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.

    Time frame: Baseline, Week 4

  26. CFB in Body Weight at Week 6 (Non-diabetic Participants With Obesity)

    Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.

    Time frame: Baseline, Week 6

  27. CFB in Body Weight at Week 8 (Non-diabetic Participants With Obesity)

    Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.

    Time frame: Baseline, Week 8

  28. CFB in Body Weight at Week 10 (Non-diabetic Participants With Obesity)

    Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.

    Time frame: Baseline, Week 10

  29. CFB in Body Weight at Week 12 (Non-diabetic Participants With Obesity)

    Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.

    Time frame: Baseline, Week 12

07

Results

Posted Dec 8, 2022

Participant flow

Participants were enrolled from 06 January 2021 to 17 November 2021 in the United States.

Treatment Period
Participant flow — Treatment Period
MilestonePlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)Placebo (Non-diabetic Obesity)PF-06882961 200 mg BID (Non-diabetic Obesity)
Started162022222221622
Completed13131613131056
Not completed3769911116
Withdrew: Adverse event164678012
Withdrew: Lost to follow-up00200302
Withdrew: No longer meets eligibility criteria00010000
Withdrew: Other01000000
Withdrew: Withdrawal by subject20022012
Follow-up Period
Participant flow — Follow-up Period
MilestonePlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)Placebo (Non-diabetic Obesity)PF-06882961 200 mg BID (Non-diabetic Obesity)
Started162022222221622
Completed131718161614514
Not completed33466718
Withdrew: Adverse event11234303
Withdrew: Lost to follow-up01200403
Withdrew: No longer meets eligibility criteria00010000
Withdrew: Other01000000
Withdrew: Withdrawal by subject20022012

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (AEs) by Severity

An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment. AEs presented below were TEAEs. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE. Assessments of AE intensity were defined as mild (easily tolerated, causing minimal discomfort and not interfering with daily activities), moderate (causing sufficient discomfort and interferes with normal daily activities) and severe (preventing normal daily activities).

Time frame:
Baseline through follow-up (Day 112)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity
ParticipantsPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)Placebo (Non-diabetic Obesity)PF-06882961 200 mg BID (Non-diabetic Obesity)
All Causality - Mild5410981016
All Causality - Moderate383563311
All Causality - Severe00121101
Treatment Related - Mild24837905
Treatment Related - Moderate242373111
Treatment Related - Severe00020101
SecondaryNumber of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion.

Time frame:
Baseline through Visit 10 (Day 91)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
ParticipantsPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)Placebo (Non-diabetic Obesity)PF-06882961 200 mg BID (Non-diabetic Obesity)
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)12161720171449
SecondaryNumber of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria

Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP \>=30 mmHg; 5) change from baseline (increase or decrease) in supine DBP \>=20 mmHg.

Time frame:
Baseline through Visit 10 (Day 91)
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria
ParticipantsPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)Placebo (Non-diabetic Obesity)PF-06882961 200 mg BID (Non-diabetic Obesity)
Supine SBP <90 mmHg00000000
Supine SBP Increase >=30 mmHg00204100
Supine SBP Decrease >=30 mmHg02132112
Supine DBP <50 mmHg00000000
Supine DBP Increase >=20 mmHg10202100
Supine DBP Decrease >=20 mmHg01111111
Supine Pulse Rate <40 bpm00000000
Supine Pulse Rate >120 bpm00000000
SecondaryNumber of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria

ECG assessments included pulse rate (PR), QT, heart rate, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300 msec, or baseline (BL) \>200 msec and \>=25% increase from BL, or BL \<=200 msec and \>=50% increase from BL; QRS interval value \>= 140msec, or \>=50% increase from BL; QTcF value \>450 and \<=480 msec, or \>480 and \<=500 msec, or \>500 msec, or increase from BL\>30 and \<=60 msec, or \>60msec.

Time frame:
Baseline through Visit 10 (Day 91)
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria
ParticipantsPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)Placebo (Non-diabetic Obesity)PF-06882961 200 mg BID (Non-diabetic Obesity)
PR interval >=300 msec00000000
%Change in PR interval >=25/50%00000000
QRS interval >=140 msec00000000
%Change in QRS interval >=50%00000000
QTcF interval >450 and <=480 msec10020011
QTcF interval >480 and <=500 msec00000010
QTcF interval >500 msec00000000
Change in QTcF interval >30 and <=60 msec20013000
Change in QTcF interval >60 msec00000010
SecondaryNumber of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. Participants who responded "yes" to the questions will be counted. Data relevant to the assessment of suicidality were mapped to the Columbia-Classification Algorithm of Suicide Assessment (C-CASA) codes.

Time frame:
Week 0, 2, 4, 6, 8, 10, 12, 13-14
Reported as:
Count of participants · Participants
Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsPlacebo (T2DM)Placebo (Non-diabetic Obesity)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)PF-06882961 200 mg BID (Non-diabetic Obesity)
Week 0 - <1> Completed Suicide00000000
Week 0 - <2> Suicide Attempt00000000
Week 0 - <3> Preparatory Acts Towards Imminent Suicidal Behavior00000000
Week 0 - <4> Suicidal Ideation00000000
Week 0 - <7> Self-injurious Behavior, No Suicidal Intent00000000
Week 2 - <1> Completed Suicide00000000
Week 2 - <2> Suicide Attempt00000000
Week 2 - <3> Preparatory Acts Towards Imminent Suicidal Behavior00000000
Week 2 - <4> Suicidal Ideation00000000
Week 2 - <7> Self-injurious Behavior, No Suicidal Intent00000000
Week 4 - <1> Completed Suicide00000000
Week 4 - <2> Suicide Attempt00000000
Week 4 - <3> Preparatory Acts Towards Imminent Suicidal Behavior00000000
Week 4 - <4> Suicidal Ideation00000000
Week 4 - <7> Self-injurious Behavior, No Suicidal Intent00000000
Week 6 - <1> Completed Suicide00000000
Week 6 - <2> Suicide Attempt00000000
Week 6 - <3> Preparatory Acts Towards Imminent Suicidal Behavior00000000
Week 6 - <4> Suicidal Ideation00000000
Week 6 - <7> Self-injurious Behavior, No Suicidal Intent00000000
Week 8 - <1> Completed Suicide00000000
Week 8 - <2> Suicide Attempt00000000
Week 8 - <3> Preparatory Acts Towards Imminent Suicidal Behavior00000000
Week 8 - <4> Suicidal Ideation00000000
Week 8 - <7> Self-injurious Behavior, No Suicidal Intent00000000
Week 10 - <1> Completed Suicide00000000
Week 10 - <2> Suicide Attempt00000000
Week 10 - <3> Preparatory Acts Towards Imminent Suicidal Behavior00000000
Week 10 - <4> Suicidal Ideation00000000
Week 10 - <7> Self-injurious Behavior, No Suicidal Intent00000000
Week 12 - <1> Completed Suicide00000000
Week 12 - <2> Suicide Attempt00000000
Week 12 - <3> Preparatory Acts Towards Imminent Suicidal Behavior00000000
Week 12 - <4> Suicidal Ideation00000000
Week 12 - <7> Self-injurious Behavior, No Suicidal Intent00000000
Follow-Up - <1> Completed Suicide00000000
Follow-Up - <2> Suicide Attempt00000000
Follow-Up - <3> Preparatory Acts Towards Imminent Suicidal Behavior00000000
Follow-Up - <4> Suicidal Ideation00000000
Follow-Up - <7> Self-injurious Behavior, No Suicidal Intent00000000
SecondaryNumber of Participants With Response to Patient Health Questionnaire-9 (PHQ-9)

The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The PHQ-9 were completed by participants and reviewed by site staff at the pre-defined time points.

Time frame:
Week 0, 2, 4, 6, 8, 10, 12, 13-14.
Reported as:
Count of participants · Participants
Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9)
ParticipantsPlacebo (T2DM)Placebo (Non-diabetic Obesity)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)PF-06882961 200 mg BID (Non-diabetic Obesity)
Week 0 - Little Interest/Pleasure in Things - Not At All156162020201921
Week 0 - Little Interest/Pleasure in Things - Several Days10311111
Week 0 - Little Interest/Pleasure in Things - More Than Half the Days00110110
Week 0 - Little Interest/Pleasure in Things - Nearly Every Day00000000
Week 0 - Feeling Down Depressed or Hopeless - Not At All146191819221919
Week 0 - Feeling Down Depressed or Hopeless - Several Days20131023
Week 0 - Feeling Down Depressed or Hopeless - More Than Half the Days00011000
Week 0 - Feeling Down Depressed or Hopeless - Nearly Every Day00000000
Week 0 - Trouble Falling or Staying Asleep - Not At All155131617171715
Week 0 - Trouble Falling or Staying Asleep - Several Days10542427
Week 0 - Trouble Falling or Staying Asleep - More Than Half the Days01212110
Week 0 - Trouble Falling or Staying Asleep - Nearly Every Day00010010
Week 0 - Feeling Tired or Little Energy - Not At All133131517161415
Week 0 - Feeling Tired or Little Energy - Several Days32544467
Week 0 - Feeling Tired or Little Energy - More Than Half the Days01220210
Week 0 - Feeling Tired or Little Energy - Nearly Every Day00010000
Week 0 - Poor Appetite or Overeating - Not At All153131918192120
Week 0 - Poor Appetite or Overeating - Several Days12613201
Week 0 - Poor Appetite or Overeating - More Than Half the Days01120101
Week 0 - Poor Appetite or Overeating - Nearly Every Day00000000
Week 0 - Feeling Bad About Yourself - Not At All166202220222121
Week 0 - Feeling Bad About Yourself - Several Days00001001
Week 0 - Feeling Bad About Yourself - More Than Half the Days00000000
Week 0 - Feeling Bad About Yourself - Nearly Every Day00000000
Week 0 - Trouble Concentrating on Things - Not At All165162119202120
Week 0 - Trouble Concentrating on Things - Several Days01311202
Week 0 - Trouble Concentrating on Things - More Than Half the Days00101000
Week 0 - Trouble Concentrating on Things - Nearly Every Day00000000
Week 0 - Moving Slowly or Fidgety/Restless - Not At All166192221212121
Week 0 - Moving Slowly or Fidgety/Restless - Several Days00100101
Week 0 - Moving Slowly or Fidgety/Restless - More Than Half the Days00000000
Week 0 - Moving Slowly or Fidgety/Restless - Nearly Every Day00000000
Week 0 - Thoughts You Be Better Off Dead - Not At All166202221222122
Week 0 - Thoughts You Be Better Off Dead - Several Days00000000
Week 0 - Thoughts You Be Better Off Dead - More Than Half the Days00000000
Week 0 - Thoughts You Be Better Off Dead - Nearly Every Day00000000
Week 2 - Little Interest/Pleasure in Things - Not At All135161721191618
Week 2 - Little Interest/Pleasure in Things - Several Days11420221
Week 2 - Little Interest/Pleasure in Things - More Than Half the Days00010010
Week 2 - Little Interest/Pleasure in Things - Nearly Every Day00010001
Week 2 - Feeling Down Depressed or Hopeless - Not At All126182021211718
Week 2 - Feeling Down Depressed or Hopeless - Several Days20210022
Week 2 - Feeling Down Depressed or Hopeless - More Than Half the Days00000000
Week 2 - Feeling Down Depressed or Hopeless - Nearly Every Day00000000
Week 2 - Trouble Falling or Staying Asleep - Not At All144141619171315
Week 2 - Trouble Falling or Staying Asleep - Several Days01522345
Week 2 - Trouble Falling or Staying Asleep - More Than Half the Days01120000
Week 2 - Trouble Falling or Staying Asleep - Nearly Every Day00010120
Week 2 - Feeling Tired or Little Energy - Not At All113131718171614
Week 2 - Feeling Tired or Little Energy - Several Days32623325
Week 2 - Feeling Tired or Little Energy - More Than Half the Days01020111
Week 2 - Feeling Tired or Little Energy - Nearly Every Day00100000
Week 2 - Poor Appetite or Overeating - Not At All122151519181717
Week 2 - Poor Appetite or Overeating - Several Days23462222
Week 2 - Poor Appetite or Overeating - More Than Half the Days01000101
Week 2 - Poor Appetite or Overeating - Nearly Every Day00100000
Week 2 - Feeling Bad About Yourself - Not At All146182121201919
Week 2 - Feeling Bad About Yourself - Several Days00100101
Week 2 - Feeling Bad About Yourself - More Than Half the Days00100000
Week 2 - Feeling Bad About Yourself - Nearly Every Day00000000
Week 2 - Trouble Concentrating on Things - Not At All145172020191818
Week 2 - Trouble Concentrating on Things - Several Days00211212
Week 2 - Trouble Concentrating on Things - More Than Half the Days01000000
Week 2 - Trouble Concentrating on Things - Nearly Every Day00100000
Week 2 - Moving Slowly or Fidgety/Restless - Not At All145192021211820
Week 2 - Moving Slowly or Fidgety/Restless - Several Days00010010
Week 2 - Moving Slowly or Fidgety/Restless - More Than Half the Days01100000
Week 2 - Moving Slowly or Fidgety/Restless - Nearly Every Day00000000
Week 2 - Thoughts You Be Better Off Dead - Not At All146202121211920
Week 2 - Thoughts You Be Better Off Dead - Several Days00000000
Week 2 - Thoughts You Be Better Off Dead - More Than Half the Days00000000
Week 2 - Thoughts You Be Better Off Dead - Nearly Every Day00000000
Week 4 - Little Interest/Pleasure in Things - Not At All124162021191816
Week 4 - Little Interest/Pleasure in Things - Several Days20300311
Week 4 - Little Interest/Pleasure in Things - More Than Half the Days01010000
Week 4 - Little Interest/Pleasure in Things - Nearly Every Day00000000
Week 4 -Feeling Down Depressed or Hopeless - Not At All135181821221815
Week 4 - Feeling Down Depressed or Hopeless - Several Days10130012
Week 4 - Feeling Down Depressed or Hopeless - More Than Half the Days00000000
Week 4 - Feeling Down Depressed or Hopeless - Nearly Every Day00000000
Week 4 - Trouble Falling or Staying Asleep - Not At All133111420181614
Week 4 - Trouble Falling or Staying Asleep - Several Days11841423
Week 4 - Trouble Falling or Staying Asleep - More Than Half the Days00030000
Week 4 - Trouble Falling or Staying Asleep - Nearly Every Day01000010
Week 4 - Feeling Tired or Little Energy - Not At All11210171817149
Week 4 - Feeling Tired or Little Energy - Several Days31821548
Week 4 - Feeling Tired or Little Energy - More Than Half the Days02122000
Week 4 - Feeling Tired or Little Energy - Nearly Every Day00000010
Week 4 - Poor Appetite or Overeating - Not At All113141820161613
Week 4 - Poor Appetite or Overeating - Several Days32330322
Week 4 - Poor Appetite or Overeating - More Than Half the Days00101311
Week 4 - Poor Appetite or Overeating - Nearly Every Day00100001
Week 4 - Feeling Bad About Yourself - Not At All145192121221817
Week 4 - Feeling Bad About Yourself - Several Days00000010
Week 4 - Feeling Bad About Yourself - More Than Half the Days00000000
Week 4 - Feeling Bad About Yourself - Nearly Every Day00000000
Week 4 - Trouble Concentrating on Things - Not At All134162020211916
Week 4 - Trouble Concentrating on Things - Several Days11311101
Week 4 - Trouble Concentrating on Things - More Than Half the Days00000000
Week 4 - Trouble Concentrating on Things - Nearly Every Day00000000
Week 4 - Moving Slowly or Fidgety/Restless - Not At All144182021211917
Week 4 - Moving Slowly or Fidgety/Restless - Several Days01110100
Week 4 - Moving Slowly or Fidgety/Restless - More Than Half the Days00000000
Week 4 - Moving Slowly or Fidgety/Restless - Nearly Every Day00000000
Week 4 - Thoughts You Be Better Off Dead - Not At All145192121221917
Week 4 - Thoughts You Be Better Off Dead - Several Days00000000
Week 4 - Thoughts You Be Better Off Dead - More Than Half the Days00000000
Week 4 - Thoughts You Be Better Off Dead - Nearly Every Day00000000
Week 6 -Little Interest/Pleasure in Things - Not At All124151719161414
Week 6 -Little Interest/Pleasure in Things - Several Days21420311
Week 6 -Little Interest/Pleasure in Things - More Than Half the Days00010010
Week 6 -Little Interest/Pleasure in Things - Nearly Every Day00000000
Week 6 -Feeling Down Depressed or Hopeless - Not At All125182018181513
Week 6 -Feeling Down Depressed or Hopeless - Several Days20101112
Week 6 -Feeling Down Depressed or Hopeless - More Than Half the Days00000000
Week 6 -Feeling Down Depressed or Hopeless - Nearly Every Day00000000
Week 6 -Trouble Falling or Staying Asleep - Not At All124121416181210
Week 6 -Trouble Falling or Staying Asleep - Several Days10763134
Week 6 -Trouble Falling or Staying Asleep - More Than Half the Days11000001
Week 6 -Trouble Falling or Staying Asleep - Nearly Every Day00000010
Week 6 -Feeling Tired or Little Energy - Not At All122111615151010
Week 6 -Feeling Tired or Little Energy - Several Days22734455
Week 6 -Feeling Tired or Little Energy - More Than Half the Days01010010
Week 6 -Feeling Tired or Little Energy - Nearly Every Day00100000
Week 6 -Poor Appetite or Overeating - Not At All12214141513912
Week 6 -Poor Appetite or Overeating - Several Days22463363
Week 6 -Poor Appetite or Overeating - More Than Half the Days01001310
Week 6 -Poor Appetite or Overeating - Nearly Every Day00100000
Week 6 -Feeling Bad About Yourself - Not At All145182019191615
Week 6 -Feeling Bad About Yourself - Several Days00100000
Week 6 -Feeling Bad About Yourself - More Than Half the Days00000000
Week 6 -Feeling Bad About Yourself - Nearly Every Day00000000
Week 6 -Trouble Concentrating on Things - Not At All134141919181614
Week 6 -Trouble Concentrating on Things - Several Days11510101
Week 6 -Trouble Concentrating on Things - More Than Half the Days00000000
Week 6 -Trouble Concentrating on Things - Nearly Every Day00000000
Week 6 -Moving Slowly or Fidgety/Restless - Not At All145182019181615
Week 6 -Moving Slowly or Fidgety/Restless - Several Days00100100
Week 6 -Moving Slowly or Fidgety/Restless - More Than Half the Days00000000
Week 6 -Moving Slowly or Fidgety/Restless - Nearly Every Day00000000
Week 6 - Thoughts You Be Better Off Dead - Not At All145182019191615
Week 6 - Thoughts You Be Better Off Dead - Several Days00100000
Week 6 - Thoughts You Be Better Off Dead - More Than Half the Days00000000
Week 6 - Thoughts You Be Better Off Dead - Nearly Every Day00000000
Week 8 - Little Interest/Pleasure in Things - Not At All135161618171513
Week 8 - Little Interest/Pleasure in Things - Several Days10220112
Week 8 - Little Interest/Pleasure in Things - More Than Half the Days00000000
Week 8 - Little Interest/Pleasure in Things - Nearly Every Day00000000
Week 8 - Feeling Down Depressed or Hopeless - Not At All145181716181514
Week 8 - Feeling Down Depressed or Hopeless - Several Days00012011
Week 8 - Feeling Down Depressed or Hopeless - More Than Half the Days00000000
Week 8 - Feeling Down Depressed or Hopeless - Nearly Every Day00000000
Week 8 - Trouble Falling or Staying Asleep - Not At All133121315171310
Week 8 - Trouble Falling or Staying Asleep - Several Days11553125
Week 8 - Trouble Falling or Staying Asleep - More Than Half the Days01100000
Week 8 - Trouble Falling or Staying Asleep - Nearly Every Day00000010
Week 8 - Feeling Tired or Little Energy - Not At All11313161616910
Week 8 - Feeling Tired or Little Energy - Several Days32412264
Week 8 - Feeling Tired or Little Energy - More Than Half the Days00110011
Week 8 - Feeling Tired or Little Energy - Nearly Every Day00000000
Week 8 - Poor Appetite or Overeating - Not At All11215131513912
Week 8 - Poor Appetite or Overeating - Several Days32353343
Week 8 - Poor Appetite or Overeating - More Than Half the Days01000220
Week 8 - Poor Appetite or Overeating - Nearly Every Day00000010
Week 8 - Feeling Bad About Yourself - Not At All145181818181514
Week 8 - Feeling Bad About Yourself - Several Days00000011
Week 8 - Feeling Bad About Yourself - More Than Half the Days00000000
Week 8 - Feeling Bad About Yourself - Nearly Every Day00000000
Week 8 - Trouble Concentrating on Things - Not At All134141618171514
Week 8 - Trouble Concentrating on Things - Several Days11320111
Week 8 - Trouble Concentrating on Things - More Than Half the Days00000000
Week 8 - Trouble Concentrating on Things - Nearly Every Day00100000
Week 8 - Moving Slowly or Fidgety/Restless - Not At All145171818181615
Week 8 - Moving Slowly or Fidgety/Restless - Several Days00100000
Week 8 - Moving Slowly or Fidgety/Restless - More Than Half the Days00000000
Week 8 - Moving Slowly or Fidgety/Restless - Nearly Every Day00000000
Week 8 - Thoughts You Be Better Off Dead - Not At All145181818181615
Week 8 - Thoughts You Be Better Off Dead - Several Days00000000
Week 8 - Thoughts You Be Better Off Dead - More Than Half the Days00000000
Week 8 - Thoughts You Be Better Off Dead - Nearly Every Day00000000
Week 10 - Little Interest/Pleasure in Things - Not At All135171516161413
Week 10 - Little Interest/Pleasure in Things - Several Days10110112
Week 10 - Little Interest/Pleasure in Things - More Than Half the Days00020000
Week 10 - Little Interest/Pleasure in Things - Nearly Every Day00000000
Week 10 - Feeling Down Depressed or Hopeless - Not At All135181615171414
Week 10 - Feeling Down Depressed or Hopeless - Several Days10021011
Week 10 - Feeling Down Depressed or Hopeless - More Than Half the Days00000000
Week 10 - Feeling Down Depressed or Hopeless - Nearly Every Day00000000
Week 10 - Trouble Falling or Staying Asleep - Not At All133131414151210
Week 10 - Trouble Falling or Staying Asleep - Several Days11532125
Week 10 - Trouble Falling or Staying Asleep - More Than Half the Days01010100
Week 10 - Trouble Falling or Staying Asleep - Nearly Every Day00000010
Week 10 - Feeling Tired or Little Energy - Not At All11211141413129
Week 10 - Feeling Tired or Little Energy - Several Days32732225
Week 10 - Feeling Tired or Little Energy - More Than Half the Days01000201
Week 10 - Feeling Tired or Little Energy - Nearly Every Day00010010
Week 10 - Poor Appetite or Overeating - Not At All102151614111012
Week 10 - Poor Appetite or Overeating - Several Days43321523
Week 10 - Poor Appetite or Overeating - More Than Half the Days00001120
Week 10 - Poor Appetite or Overeating - Nearly Every Day00000010
Week 10 - Feeling Bad About Yourself - Not At All145181816171415
Week 10 - Feeling Bad About Yourself - Several Days00000010
Week 10 - Feeling Bad About Yourself - More Than Half the Days00000000
Week 10 - Feeling Bad About Yourself - Nearly Every Day00000000
Week 10 - Trouble Concentrating on Things - Not At All135171716161515
Week 10 - Trouble Concentrating on Things - Several Days10110100
Week 10 - Trouble Concentrating on Things - More Than Half the Days00000000
Week 10 - Trouble Concentrating on Things - Nearly Every Day00000000
Week 10 - Moving Slowly or Fidgety/Restless - Not At All145171716161515
Week 10 - Moving Slowly or Fidgety/Restless - Several Days00100100
Week 10 - Moving Slowly or Fidgety/Restless - More Than Half the Days00010000
Week 10 - Moving Slowly or Fidgety/Restless - Nearly Every Day00000000
Week 10 - Thoughts You Be Better Off Dead - Not At All145181816171515
Week 10 - Thoughts You Be Better Off Dead - Several Days00000000
Week 10 - Thoughts You Be Better Off Dead - More Than Half the Days00000000
Week 10 - Thoughts You Be Better Off Dead - Nearly Every Day00000000
Week 12 - Little Interest/Pleasure in Things - Not At All115151416161314
Week 12 - Little Interest/Pleasure in Things - Several Days20320010
Week 12 - Little Interest/Pleasure in Things - More Than Half the Days00020000
Week 12 - Little Interest/Pleasure in Things - Nearly Every Day00000000
Week 12 - Feeling Down Depressed or Hopeless - Not At All115181716161314
Week 12 - Feeling Down Depressed or Hopeless - Several Days20010010
Week 12 - Feeling Down Depressed or Hopeless - More Than Half the Days00000000
Week 12 - Feeling Down Depressed or Hopeless - Nearly Every Day00000000
Week 12 - Trouble Falling or Staying Asleep - Not At All11312121514129
Week 12 - Trouble Falling or Staying Asleep - Several Days22651114
Week 12 - Trouble Falling or Staying Asleep - More Than Half the Days00010101
Week 12 - Trouble Falling or Staying Asleep - Nearly Every Day00000010
Week 12 - Feeling Tired or Little Energy - Not At All10312141414119
Week 12 - Feeling Tired or Little Energy - Several Days32632235
Week 12 - Feeling Tired or Little Energy - More Than Half the Days00000000
Week 12 - Feeling Tired or Little Energy - Nearly Every Day00010000
Week 12 - Poor Appetite or Overeating - Not At All10214131414912
Week 12 - Poor Appetite or Overeating - Several Days33352241
Week 12 - Poor Appetite or Overeating - More Than Half the Days00000000
Week 12 - Poor Appetite or Overeating - Nearly Every Day00100011
Week 12 - Feeling Bad About Yourself - Not At All135181816161314
Week 12 - Feeling Bad About Yourself - Several Days00000010
Week 12 - Feeling Bad About Yourself - More Than Half the Days00000000
Week 12 - Feeling Bad About Yourself - Nearly Every Day00000000
Week 12 - Trouble Concentrating on Things - Not At All115171716161414
Week 12 - Trouble Concentrating on Things - Several Days20100000
Week 12 - Trouble Concentrating on Things - More Than Half the Days00010000
Week 12 - Trouble Concentrating on Things - Nearly Every Day00000000
Week 12 - Moving Slowly or Fidgety/Restless - Not At All125171816161414
Week 12 - Moving Slowly or Fidgety/Restless - Several Days10100000
Week 12 - Moving Slowly or Fidgety/Restless - More Than Half the Days00000000
Week 12 - Moving Slowly or Fidgety/Restless - Nearly Every Day00000000
Week 12 - Thoughts You Be Better Off Dead - Not At All135181816161414
Week 12 - Thoughts You Be Better Off Dead - Several Days00000000
Week 12 - Thoughts You Be Better Off Dead - More Than Half the Days00000000
Week 12 - Thoughts You Be Better Off Dead - Nearly Every Day00000000
Follow-Up - Little Interest/Pleasure in Things - Not At All115141716171312
Follow-Up - Little Interest/Pleasure in Things - Several Days20310011
Follow-Up - Little Interest/Pleasure in Things - More Than Half the Days00000001
Follow-Up - Little Interest/Pleasure in Things - Nearly Every Day00000000
Follow-Up - Feeling Down Depressed or Hopeless - Not At All135171716161312
Follow-Up - Feeling Down Depressed or Hopeless - Several Days00010112
Follow-Up - Feeling Down Depressed or Hopeless - More Than Half the Days00000000
Follow-Up - Feeling Down Depressed or Hopeless - Nearly Every Day00000000
Follow-Up - Trouble Falling or Staying Asleep - Not At All12412131415129
Follow-Up - Trouble Falling or Staying Asleep - Several Days01552214
Follow-Up - Trouble Falling or Staying Asleep - More Than Half the Days10000000
Follow-Up - Trouble Falling or Staying Asleep - Nearly Every Day00000011
Follow-Up - Feeling Tired or Little Energy - Not At All11211141417129
Follow-Up - Feeling Tired or Little Energy - Several Days23542024
Follow-Up - Feeling Tired or Little Energy - More Than Half the Days00100001
Follow-Up - Feeling Tired or Little Energy - Nearly Every Day00000000
Follow-Up - Poor Appetite or Overeating - Not At All113131615161212
Follow-Up - Poor Appetite or Overeating - Several Days22421121
Follow-Up - Poor Appetite or Overeating - More Than Half the Days00000001
Follow-Up - Poor Appetite or Overeating - Nearly Every Day00000000
Follow-Up - Feeling Bad About Yourself - Not At All135171816171313
Follow-Up - Feeling Bad About Yourself - Several Days00000010
Follow-Up - Feeling Bad About Yourself - More Than Half the Days00000001
Follow-Up - Feeling Bad About Yourself - Nearly Every Day00000000
Follow-Up - Trouble Concentrating on Things - Not At All125171616171413
Follow-Up - Trouble Concentrating on Things - Several Days10020001
Follow-Up - Trouble Concentrating on Things - More Than Half the Days00000000
Follow-Up - Trouble Concentrating on Things - Nearly Every Day00000000
Follow-Up - Moving Slowly or Fidgety/Restless - Not At All125171816171414
Follow-Up - Moving Slowly or Fidgety/Restless - Several Days10000000
Follow-Up - Moving Slowly or Fidgety/Restless - More Than Half the Days00000000
Follow-Up - Moving Slowly or Fidgety/Restless - Nearly Every Day00000000
Follow-Up - Thoughts You Be Better Off Dead - Not At All135171816171414
Follow-Up - Thoughts You Be Better Off Dead - Several Days00000000
Follow-Up - Thoughts You Be Better Off Dead - More Than Half the Days00000000
Follow-Up - Thoughts You Be Better Off Dead - Nearly Every Day00000000
SecondaryChange From Baseline (CFB) in Fasting Plasma Glucose at Week 2

Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

Time frame:
Baseline, Week 2
Reported as:
Least squares mean · mg/dL
Change From Baseline (CFB) in Fasting Plasma Glucose at Week 2
mg/dLPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
Change From Baseline (CFB) in Fasting Plasma Glucose at Week 2-5.63 (-19.00 to 7.74)-3.32 (-14.62 to 7.97)-23.04 (-34.05 to -12.03)-36.48 (-47.44 to -25.52)-39.29 (-50.23 to -28.35)-25.15 (-36.59 to -13.72)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.5863 (1-Sided) · Mean difference (final values): 2.31 · 90% CI -15.23 to 19.85Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.0494 (1-Sided) · Mean difference (final values): -17.41 · 90% CI -34.75 to -0.06Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = 0.0019 (1-Sided) · Mean difference (final values): -30.85 · 90% CI -48.09 to -13.61Test = PF06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.0009 (1-Sided) · Mean difference (final values): -33.66 · 90% CI -51.00 to -16.32Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.0343 (1-Sided) · Mean difference (final values): -19.52 · 90% CI -37.12 to -1.92Test = PF-06882961 Reference = Placebo
SecondaryCFB in Fasting Plasma Glucose at Week 4

Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

Time frame:
Baseline, Week 4
Reported as:
Least squares mean · mg/dL
CFB in Fasting Plasma Glucose at Week 4
mg/dLPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Fasting Plasma Glucose at Week 4-13.12 (-26.88 to 0.64)-16.45 (-28.11 to -4.79)-32.77 (-43.98 to -21.55)-45.92 (-57.20 to -34.64)-48.97 (-60.52 to -37.42)-41.60 (-53.38 to -29.83)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.3804 (1-Sided) · Mean difference (final values): -3.33 · 90% CI -21.41 to 14.76Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.0348 (1-Sided) · Mean difference (final values): -19.65 · 90% CI -37.44 to -1.87Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = 0.0014 (1-Sided) · Mean difference (final values): -32.80 · 90% CI -50.54 to -15.05Test = PF06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.0007 (1-Sided) · Mean difference (final values): -35.85 · 90% CI -53.90 to -17.81Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.0052 (1-Sided) · Mean difference (final values): -28.49 · 90% CI -46.60 to -10.37Test = PF-06882961 Reference = Placebo
SecondaryCFB in Fasting Plasma Glucose at Week 6

Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · mg/dL
CFB in Fasting Plasma Glucose at Week 6
mg/dLPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Fasting Plasma Glucose at Week 6-3.75 (-19.85 to 12.35)-29.33 (-43.35 to -15.31)-36.70 (-50.13 to -23.27)-43.82 (-57.90 to -29.75)-49.22 (-63.14 to -35.31)-37.38 (-51.77 to -22.99)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.0250 (1-Sided) · Mean difference (final values): -25.58 · 90% CI -46.97 to -4.18Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.0053 (1-Sided) · Mean difference (final values): -32.95 · 90% CI -53.95 to -11.95Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = 0.0012 · Mean difference (final values): -40.07 · 90% CI -61.41 to -18.73Test = PF06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.0003 (1-Sided) · Mean difference (final values): -45.47 · 90% CI -66.85 to -24.10Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.0055 (1-Sided) · Mean difference (final values): -33.63 · 90% CI -55.19 to -12.08Test = PF-06882961 Reference = Placebo
SecondaryCFB in Fasting Plasma Glucose at Week 8

Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · mg/dL
CFB in Fasting Plasma Glucose at Week 8
mg/dLPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Fasting Plasma Glucose at Week 8-5.90 (-20.83 to 9.04)-33.69 (-47.42 to -19.96)-31.57 (-44.56 to -18.58)-52.84 (-66.55 to -39.13)-39.69 (-53.63 to -25.75)-48.02 (-62.47 to -33.57)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.0127 (1-Sided) · Mean difference (final values): -27.79 · 90% CI -48.12 to -7.47Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.0171 (1-Sided) · Mean difference (final values): -25.67 · 90% CI -45.51 to -5.83Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = 0.0001 (1-Sided) · Mean difference (final values): -46.94 · 90% CI -67.16 to -26.72Test = PF06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.0037 (1-Sided) · Mean difference (final values): -33.79 · 90% CI -54.32 to -13.27Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.0005 (1-Sided) · Mean difference (final values): -42.13 · 90% CI -62.85 to -21.40Test = PF-06882961 Reference = Placebo
SecondaryCFB in Fasting Plasma Glucose at Week 10

Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

Time frame:
Baseline, Week 10
Reported as:
Least squares mean · mg/dL
CFB in Fasting Plasma Glucose at Week 10
mg/dLPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Fasting Plasma Glucose at Week 10-23.39 (-39.07 to -7.71)-36.24 (-51.69 to -20.78)-38.21 (-52.17 to -24.26)-57.36 (-72.43 to -42.29)-22.08 (-36.88 to -7.29)-37.81 (-53.52 to -22.11)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.1678 (1-Sided) · Mean difference (final values): -12.85 · 90% CI -34.90 to 9.21Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.1223 (1-Sided) · Mean difference (final values): -14.82 · 90% CI -35.85 to 6.21Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = 0.0054 (1-Sided) · Mean difference (final values): -33.97 · 90% CI -55.66 to -12.28Test = PF06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.5398 (1-Sided) · Mean difference (final values): 1.31 · 90% CI -20.38 to 22.99Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.1409 (1-Sided) · Mean difference (final values): -14.42 · 90% CI -36.56 to 7.72Test = PF-06882961 Reference = Placebo
SecondaryCFB in Fasting Plasma Glucose at Week 12

Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · mg/dL
CFB in Fasting Plasma Glucose at Week 12
mg/dLPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Fasting Plasma Glucose at Week 12-13.09 (-29.75 to 3.57)-41.74 (-58.49 to -25.00)-40.41 (-55.25 to -25.57)-53.94 (-70.26 to -37.63)-23.34 (-39.52 to -7.17)-37.48 (-55.27 to -19.69)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.0236 (1-Sided) · Mean difference (final values): -28.65 · 90% CI -52.31 to -4.99Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.0226 (1-Sided) · Mean difference (final values): -27.32 · 90% CI -49.67 to -4.97Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = 0.0022 (1-Sided) · Mean difference (final values): -40.85 · 90% CI -64.11 to -17.59Test = PF06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.2335 (1-Sided) · Mean difference (final values): -10.25 · 90% CI -33.59 to 13.08Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.0494 (1-Sided) · Mean difference (final values): -24.38 · 90% CI -48.69 to -0.08Test = PF-06882961 Reference = Placebo
SecondaryCFB in Glycolated Hemoglobin A1c (HbA1c) at Week 2

Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

Time frame:
Baseline, Week 2
Reported as:
Least squares mean · Percentage
CFB in Glycolated Hemoglobin A1c (HbA1c) at Week 2
PercentagePlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Glycolated Hemoglobin A1c (HbA1c) at Week 2-0.03 (-0.20 to 0.14)-0.12 (-0.26 to 0.02)-0.29 (-0.43 to -0.15)-0.37 (-0.51 to -0.24)-0.35 (-0.49 to -0.21)-0.20 (-0.34 to -0.05)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.2485 (1-Sided) · Mean difference (final values): -0.09 · 90% CI -0.31 to 0.13Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.0252 (1-Sided) · Mean difference (final values): -0.26 · 90% CI -0.48 to -0.04Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = 0.0053 (1-Sided) · Mean difference (final values): -0.34 · 90% CI -0.56 to -0.12Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.0090 (1-Sided) · Mean difference (final values): -0.32 · 90% CI -0.54 to -0.10Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.1066 (1-Sided) · Mean difference (final values): -0.17 · 90% CI -0.39 to 0.05Test = PF-06882961 Reference = Placebo
SecondaryCFB in Glycolated HbA1c at Week 4

Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

Time frame:
Baseline, Week 4
Reported as:
Least squares mean · Percentage
CFB in Glycolated HbA1c at Week 4
PercentagePlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Glycolated HbA1c at Week 4-0.22 (-0.45 to 0.00)-0.33 (-0.52 to -0.14)-0.59 (-0.77 to -0.41)-0.81 (-1.00 to -0.63)-0.75 (-0.94 to -0.56)-0.58 (-0.78 to -0.39)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.2740 (1-Sided) · Mean difference (final values): -0.11 · 90% CI -0.40 to 0.19Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.0196 (1-Sided) · Mean difference (final values): -0.37 · 90% CI -0.66 to -0.08Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = 0.0006 · Mean difference (final values): -0.59 · 90% CI -0.88 to -0.30Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.0019 (1-Sided) · Mean difference (final values): -0.53 · 90% CI -0.82 to -0.23Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.0243 (1-Sided) · Mean difference (final values): -0.36 · 90% CI -0.66 to -0.06Test = PF-06882961 Reference = Placebo
SecondaryCFB in Glycolated HbA1c at Week 6

Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · Percentage
CFB in Glycolated HbA1c at Week 6
PercentagePlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Glycolated HbA1c at Week 6-0.26 (-0.56 to 0.04)-0.49 (-0.75 to -0.24)-0.92 (-1.16 to -0.67)-1.11 (-1.36 to -0.86)-0.97 (-1.22 to -0.72)-0.93 (-1.19 to -0.68)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.1587 (1-Sided) · Mean difference (final values): -0.23 · 90% CI -0.62 to 0.15Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.0027 (1-Sided) · Mean difference (final values): -0.66 · 90% CI -1.04 to -0.27Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = 0.0002 (1-Sided) · Mean difference (final values): -0.85 · 90% CI -1.24 to -0.47Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.0016 (1-Sided) · Mean difference (final values): -0.71 · 90% CI -1.10 to -0.32Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.0027 (1-Sided) · Mean difference (final values): -0.67 · 90% CI -1.07 to -0.28Test = PF-06882961 Reference = Placebo
SecondaryCFB in Glycolated HbA1c at Week 8

Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · Percentage
CFB in Glycolated HbA1c at Week 8
PercentagePlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Glycolated HbA1c at Week 8-0.27 (-0.60 to 0.05)-0.71 (-0.99 to -0.43)-1.14 (-1.41 to -0.88)-1.38 (-1.65 to -1.10)-1.20 (-1.48 to -0.92)-1.18 (-1.47 to -0.89)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.0472 (1-Sided) · Mean difference (final values): -0.43 · 90% CI -0.86 to -0.01Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.0004 (1-Sided) · Mean difference (final values): -0.87 · 90% CI -1.29 to -0.45Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = <0.0001 (1-Sided) · Mean difference (final values): -1.10 · 90% CI -1.53 to -0.68Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.0003 (1-Sided) · Mean difference (final values): -0.93 · 90% CI -1.36 to -0.50Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.0004 (1-Sided) · Mean difference (final values): -0.91 · 90% CI -1.34 to -0.47Test = PF-06882961 Reference = Placebo
SecondaryCFB in Glycolated HbA1c at Week 10

Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

Time frame:
Baseline, Week 10
Reported as:
Least squares mean · Percentage
CFB in Glycolated HbA1c at Week 10
PercentagePlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Glycolated HbA1c at Week 10-0.32 (-0.69 to 0.05)-1.00 (-1.33 to -0.67)-1.26 (-1.57 to -0.95)-1.48 (-1.81 to -1.16)-1.22 (-1.55 to -0.89)-1.36 (-1.70 to -1.03)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.0116 (1-Sided) · Mean difference (final values): -0.69 · 90% CI -1.18 to -0.19Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.0008 · Mean difference (final values): -0.94 · 90% CI -1.43 to -0.46Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = <0.0001 (1-Sided) · Mean difference (final values): -1.16 · 90% CI -1.66 to -0.67Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.0017 (1-Sided) · Mean difference (final values): -0.90 · 90% CI -1.40 to -0.40Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.0004 (1-Sided) · Mean difference (final values): -1.05 · 90% CI -1.55 to -0.55Test = PF-06882961 Reference = Placebo
SecondaryCFB in Glycolated HbA1c at Week 12

Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Percentage
CFB in Glycolated HbA1c at Week 12
PercentagePlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Glycolated HbA1c at Week 12-0.32 (-0.73 to 0.10)-1.07 (-1.45 to -0.70)-1.32 (-1.67 to -0.97)-1.56 (-1.94 to -1.19)-1.04 (-1.42 to -0.67)-1.57 (-1.96 to -1.18)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.0132 (1-Sided) · Mean difference (final values): -0.76 · 90% CI -1.32 to -0.20Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.0014 (1-Sided) · Mean difference (final values): -1.00 · 90% CI -1.55 to -0.46Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = 0.0002 (1-Sided) · Mean difference (final values): -1.25 · 90% CI -1.80 to -0.69Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.0174 · Mean difference (final values): -0.73 · 90% CI -1.29 to -0.16Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.0002 (1-Sided) · Mean difference (final values): -1.25 · 90% CI -1.82 to -0.69Test = PF-06882961 Reference = Placebo
SecondaryCFB in Body Weight at Week 2 (Participants With T2DM)

Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.

Time frame:
Baseline, Week 2
Reported as:
Least squares mean · kg
CFB in Body Weight at Week 2 (Participants With T2DM)
kgPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Body Weight at Week 2 (Participants With T2DM)-0.14 (-0.72 to 0.44)-0.40 (-0.89 to 0.08)-0.22 (-0.70 to 0.26)-0.46 (-0.94 to 0.02)-0.63 (-1.11 to -0.16)-0.21 (-0.72 to 0.30)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.2843 (1-Sided) · Mean difference (final values): -0.26 · 90% CI -1.02 to 0.50Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.4310 (1-Sided) · Mean difference (final values): -0.08 · 90% CI -0.84 to 0.68Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = 0.2402 (1-Sided) · Mean difference (final values): -0.32 · 90% CI -1.07 to 0.43Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.1397 (1-Sided) · Mean difference (final values): -0.49 · 90% CI -1.24 to 0.26Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.4393 (1-Sided) · Mean difference (final values): -0.07 · 90% CI -0.85 to 0.71Test = PF-06882961 Reference = Placebo
SecondaryCFB in Body Weight at Week 4 (Participants With T2DM)

Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.

Time frame:
Baseline, Week 4
Reported as:
Least squares mean · kg
CFB in Body Weight at Week 4 (Participants With T2DM)
kgPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Body Weight at Week 4 (Participants With T2DM)-0.46 (-1.40 to 0.47)-1.23 (-2.03 to -0.44)-0.34 (-1.11 to 0.43)-1.58 (-2.35 to -0.81)-1.47 (-2.25 to -0.70)-0.41 (-1.23 to 0.41)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.1491 (1-Sided) · Mean difference (final values): -0.77 · 90% CI -2.00 to 0.45Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.5664 (1-Sided) · Median difference (final values): 0.12 · 90% CI -1.09 to 1.34Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = 0.0632 (1-Sided) · Median difference (final values): -1.12 · 90% CI -2.33 to 0.09Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.0847 (1-Sided) · Median difference (final values): -1.01 · 90% CI -2.23 to 0.20Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.5264 (1-Sided) · Mean difference (final values): 0.05 · 90% CI -1.20 to 1.30Test = PF-06882961 Reference = Placebo
SecondaryCFB in Body Weight at Week 6 (Participants With T2DM)

Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · kg
CFB in Body Weight at Week 6 (Participants With T2DM)
kgPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Body Weight at Week 6 (Participants With T2DM)-0.38 (-1.42 to 0.66)-1.86 (-2.77 to -0.95)-0.65 (-1.52 to 0.23)-2.74 (-3.65 to -1.83)-2.23 (-3.13 to -1.33)-1.16 (-2.10 to -0.21)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.0395 (1-Sided) · Mean difference (final values): -1.48 · 90% CI -2.86 to -0.10Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.3726 (1-Sided) · Mean difference (final values): -0.27 · 90% CI -1.63 to 1.10Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = 0.0028 (1-Sided) · Mean difference (final values): -2.36 · 90% CI -3.74 to -0.98Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.0139 (1-Sided) · Mean difference (final values): -1.85 · 90% CI -3.23 to -0.47Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.1815 (1-Sided) · Mean difference (final values): -0.78 · 90% CI -2.19 to 0.64Test = PF-06882961 Reference = Placebo
SecondaryCFB in Body Weight at Week 8 (Participants With T2DM)

Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · kg
CFB in Body Weight at Week 8 (Participants With T2DM)
kgPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Body Weight at Week 8 (Participants With T2DM)-0.36 (-1.51 to 0.80)-2.52 (-3.55 to -1.48)-1.08 (-2.07 to -0.09)-3.82 (-4.86 to -2.79)-2.41 (-3.43 to -1.38)-3.32 (-4.42 to -2.23)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.0112 (1-Sided) · Mean difference (final values): -2.16 · 90% CI -3.71 to -0.61Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.2161 (1-Sided) · Mean difference (final values): -0.72 · 90% CI -2.24 to 0.80Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = 0.0002 (1-Sided) · Mean difference (final values): -3.47 · 90% CI -5.02 to -1.92Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.0147 (1-Sided) · Mean difference (final values): -2.05 · 90% CI -3.59 to -0.51Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.0013 (1-Sided) · Mean difference (final values): -2.97 · 90% CI -4.56 to -1.37Test = PF-06882961 Reference = Placebo
SecondaryCFB in Body Weight at Week 10 (Participants With T2DM)

Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.

Time frame:
Baseline, Week 10
Reported as:
Least squares mean · kg
CFB in Body Weight at Week 10 (Participants With T2DM)
kgPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Body Weight at Week 10 (Participants With T2DM)-0.67 (-1.96 to 0.61)-3.14 (-4.34 to -1.93)-1.71 (-2.83 to -0.58)-4.95 (-6.15 to -3.75)-3.35 (-4.53 to -2.18)-4.38 (-5.64 to -3.12)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.0111 (1-Sided) · Mean difference (final values): -2.46 · 90% CI -4.22 to -0.70Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.1600 (1-Sided) · Mean difference (final values): -1.03 · 90% CI -2.75 to 0.68Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = <0.0001 (1-Sided) · Mean difference (final values): -4.27 · 90% CI -6.03 to -2.52Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.0061 (1-Sided) · Mean difference (final values): -2.68 · 90% CI -4.42 to -0.94Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = 0.0005 (1-Sided) · Mean difference (final values): -3.71 · 90% CI -5.52 to -1.89Test = PF-06882961 Reference = Placebo
SecondaryCFB in Body Weight at Week 12 (Participants With T2DM)

Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · kg
CFB in Body Weight at Week 12 (Participants With T2DM)
kgPlacebo (T2DM)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)
CFB in Body Weight at Week 12 (Participants With T2DM)-0.42 (-1.87 to 1.03)-3.64 (-5.03 to -2.24)-1.93 (-3.22 to -0.64)-5.38 (-6.77 to -3.98)-2.93 (-4.29 to -1.56)-5.37 (-6.86 to -3.88)
Statistical analysis
  • Placebo (T2DM) vs PF-06882961 80 mg BID Low, Slow (T2DM) · Mixed Models Analysis · p = 0.0047 (1-Sided) · Mean difference (final values): -3.21 · 90% CI -5.22 to -1.20Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 80 mg BID High, Slow (T2DM) · Mixed Models Analysis · p = 0.1003 (1-Sided) · Mean difference (final values): -1.51 · 90% CI -3.45 to 0.44Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID Low, Fast (T2DM) · Mixed Models Analysis · p = <0.0001 (1-Sided) · Mean difference (final values): -4.95 · 90% CI -6.96 to -2.95Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 120 mg BID High, Fast (T2DM) · Mixed Models Analysis · p = 0.0197 (1-Sided) · Mean difference (final values): -2.50 · 90% CI -4.49 to -0.51Test = PF-06882961 Reference = Placebo
  • Placebo (T2DM) vs PF-06882961 200 mg BID (T2DM) · Mixed Models Analysis · p = <0.0001 (1-Sided) · Mean difference (final values): -4.94 · 90% CI -7.03 to -2.85Test = PF-06882961 Reference = Placebo
SecondaryCFB in Body Weight at Week 2 (Non-diabetic Participants With Obesity)

Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.

Time frame:
Baseline, Week 2
Reported as:
Least squares mean · kg
CFB in Body Weight at Week 2 (Non-diabetic Participants With Obesity)
kgPlacebo (Non-diabetic Obesity)PF-06882961 200 mg BID (Non-diabetic Obesity)
CFB in Body Weight at Week 2 (Non-diabetic Participants With Obesity)0.23 (-0.81 to 1.26)-0.73 (-1.34 to -0.13)
Statistical analysis
  • Placebo (Non-diabetic Obesity) vs PF-06882961 200 mg BID (Non-diabetic Obesity) · Mixed Models Analysis · p = 0.0836 (1-Sided) · Mean difference (final values): -0.96 · 90% CI -2.12 to 0.19Test = PF-06882961 Reference = Placebo
SecondaryCFB in Body Weight at Week 4 (Non-diabetic Participants With Obesity)

Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.

Time frame:
Baseline, Week 4
Reported as:
Least squares mean · kg
CFB in Body Weight at Week 4 (Non-diabetic Participants With Obesity)
kgPlacebo (Non-diabetic Obesity)PF-06882961 200 mg BID (Non-diabetic Obesity)
CFB in Body Weight at Week 4 (Non-diabetic Participants With Obesity)0.09 (-1.21 to 1.40)-1.50 (-2.25 to -0.74)
Statistical analysis
  • Placebo (Non-diabetic Obesity) vs PF-06882961 200 mg BID (Non-diabetic Obesity) · Mixed Models Analysis · p = 0.0386 (1-Sided) · Mean difference (final values): -1.59 · 90% CI -3.07 to -0.12Test = PF-06882961 Reference = Placebo
SecondaryCFB in Body Weight at Week 6 (Non-diabetic Participants With Obesity)

Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · kg
CFB in Body Weight at Week 6 (Non-diabetic Participants With Obesity)
kgPlacebo (Non-diabetic Obesity)PF-06882961 200 mg BID (Non-diabetic Obesity)
CFB in Body Weight at Week 6 (Non-diabetic Participants With Obesity)-0.10 (-2.28 to 2.08)-1.59 (-2.86 to -0.33)
Statistical analysis
  • Placebo (Non-diabetic Obesity) vs PF-06882961 200 mg BID (Non-diabetic Obesity) · Mixed Models Analysis · p = 0.1566 (1-Sided) · Mean difference (final values): -1.50 · 90% CI -3.99 to 1.00Test = PF-06882961 Reference = Placebo
SecondaryCFB in Body Weight at Week 8 (Non-diabetic Participants With Obesity)

Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · kg
CFB in Body Weight at Week 8 (Non-diabetic Participants With Obesity)
kgPlacebo (Non-diabetic Obesity)PF-06882961 200 mg BID (Non-diabetic Obesity)
CFB in Body Weight at Week 8 (Non-diabetic Participants With Obesity)0.26 (-2.57 to 3.09)-2.36 (-4.08 to -0.65)
Statistical analysis
  • Placebo (Non-diabetic Obesity) vs PF-06882961 200 mg BID (Non-diabetic Obesity) · Mixed Models Analysis · p = 0.0916 (1-Sided) · Mean difference (final values): -2.62 · 90% CI -5.91 to 0.67Test = PF-06882961 Reference = Placebo
SecondaryCFB in Body Weight at Week 10 (Non-diabetic Participants With Obesity)

Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.

Time frame:
Baseline, Week 10
Reported as:
Least squares mean · kg
CFB in Body Weight at Week 10 (Non-diabetic Participants With Obesity)
kgPlacebo (Non-diabetic Obesity)PF-06882961 200 mg BID (Non-diabetic Obesity)
CFB in Body Weight at Week 10 (Non-diabetic Participants With Obesity)-0.40 (-3.17 to 2.37)-3.47 (-5.21 to -1.73)
Statistical analysis
  • Placebo (Non-diabetic Obesity) vs PF-06882961 200 mg BID (Non-diabetic Obesity) · Mixed Models Analysis · p = 0.0590 (1-Sided) · Mean difference (final values): -3.07 · 90% CI -6.31 to 0.17Test = PF-06882961 Reference = Placebo
SecondaryCFB in Body Weight at Week 12 (Non-diabetic Participants With Obesity)

Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · kg
CFB in Body Weight at Week 12 (Non-diabetic Participants With Obesity)
kgPlacebo (Non-diabetic Obesity)PF-06882961 200 mg BID (Non-diabetic Obesity)
CFB in Body Weight at Week 12 (Non-diabetic Participants With Obesity)-0.11 (-3.93 to 3.72)-3.85 (-6.25 to -1.44)
Statistical analysis
  • Placebo (Non-diabetic Obesity) vs PF-06882961 200 mg BID (Non-diabetic Obesity) · Mixed Models Analysis · p = 0.0826 (1-Sided) · Mean difference (final values): -3.74 · 90% CI -8.23 to 0.75Test = PF-06882961 Reference = Placebo

Adverse events

Collected over Baseline through follow-up (Day 112-119).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (T2DM)0/16 (0%)0/16 (0%)8/16 (50%)
Placebo (Non-diabetic Obesity)0/6 (0%)0/6 (0%)4/6 (66.7%)
PF-06882961 80 mg BID Low, Slow (T2DM)0/20 (0%)0/20 (0%)11/20 (55%)
PF-06882961 80 mg BID High, Slow (T2DM)0/22 (0%)0/22 (0%)13/22 (59.1%)
PF-06882961 120 mg BID Low, Fast (T2DM)0/22 (0%)0/22 (0%)14/22 (63.6%)
PF-06882961 120 mg BID High, Fast (T2DM)0/22 (0%)0/22 (0%)14/22 (63.6%)
PF-06882961 200 mg BID (T2DM)0/21 (0%)0/21 (0%)14/21 (66.7%)
PF-06882961 200 mg BID (Non-diabetic Obesity)0/22 (0%)0/22 (0%)18/22 (81.8%)
Most frequent other events
Showing 10 of 45
Most frequent other events
EventPlacebo (T2DM)Placebo (Non-diabetic Obesity)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)PF-06882961 200 mg BID (Non-diabetic Obesity)
NauseaGastrointestinal disorders2/160/64/205/226/228/2210/2113/22
VomitingGastrointestinal disorders2/160/65/204/226/229/226/2110/22
DiarrhoeaGastrointestinal disorders2/160/62/201/225/225/221/211/22
DyspepsiaGastrointestinal disorders0/160/61/201/222/225/221/211/22
Decreased appetiteMetabolism and nutrition disorders1/160/61/202/224/221/224/210/22
DizzinessNervous system disorders1/160/62/201/222/222/220/214/22
PalpitationsCardiac disorders0/161/60/200/222/220/220/210/22
GastroenteritisInfections and infestations0/161/60/200/220/220/220/210/22
Gastroenteritis viralInfections and infestations0/161/60/200/220/220/220/210/22
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/161/60/200/220/220/220/210/22

Baseline characteristics

A total of 151 participants were assigned to the treatment and treated with danuglipron or placebo.

Age, Continuous
Age, Continuous(Years)Placebo (T2DM)Placebo (Non-diabetic Obesity)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)PF-06882961 200 mg BID (Non-diabetic Obesity)Total
Mean (SD)53.9 ± 9.1049.5 ± 5.7959.5 ± 9.5560.9 ± 8.6958.3 ± 7.1157.2 ± 11.859 ± 9.3148.5 ± 13.1256.5 ± 10.55
Age, Continuous
Age, Continuous(Years)Placebo (T2DM)Placebo (Non-diabetic Obesity)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)PF-06882961 200 mg BID (Non-diabetic Obesity)Total
Median53.0 (39 to 69)49.0 (42 to 59)60.5 (34 to 72)61.5 (46 to 74)58.5 (41 to 71)60.0 (32 to 75)59.0 (44 to 75)52.0 (21 to 69)58.0 (21 to 75)
Age, Customized
Age, Customized(Participants)Placebo (T2DM)Placebo (Non-diabetic Obesity)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)PF-06882961 200 mg BID (Non-diabetic Obesity)Total
<18000000000
18-442110131716
45-6412512131812141399
>=652079376236
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (T2DM)Placebo (Non-diabetic Obesity)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)PF-06882961 200 mg BID (Non-diabetic Obesity)Total
Female8410101010101678
Male821012121211673
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo (T2DM)Placebo (Non-diabetic Obesity)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)PF-06882961 200 mg BID (Non-diabetic Obesity)Total
White126171919171718125
Black or African American4032253423
Asian000010102
Not reported000100001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo (T2DM)Placebo (Non-diabetic Obesity)PF-06882961 80 mg BID Low, Slow (T2DM)PF-06882961 80 mg BID High, Slow (T2DM)PF-06882961 120 mg BID Low, Fast (T2DM)PF-06882961 120 mg BID High, Fast (T2DM)PF-06882961 200 mg BID (T2DM)PF-06882961 200 mg BID (Non-diabetic Obesity)Total
Hispanic or Latino931211911151383
Not Hispanic or Latino7381113116968
08

Study locations

38 sites
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Unity Health - Searcy Medical Center
    Searcy, Arkansas 72143, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Desert Oasis Healthcare Medical Group
    Palm Springs, California 92262, United States
  • Rancho Cucamonga Clinical Research
    Rancho Cucamonga, California 91730, United States
  • California Research Foundation
    San Diego, California 92123-1881, United States
  • University Clinical Investigators, Inc.
    Tustin, California 92780, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Emerson Clinical Research Institute
    Washington, District of Columbia 20011, United States
  • Innovative Research of West Florida, Inc.
    Clearwater, Florida 33756, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Acevedo Clinical Research Associates
    Miami, Florida 33142, United States
  • Pines Care Research Center, LLC
    Pembroke Pines, Florida 33024, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Meridian Clinical Research, LLC
    Sioux City, Iowa 51106, United States
  • Research Integrity, LLC
    Owensboro, Kentucky 42303, United States
  • Nola Care LLC
    Metairie, Louisiana 70006, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • Meridian Clinical Research, LLC DBA Regional Clinical Research
    Endwell, New York 13760, United States
  • PMG Research of Raleigh, LLC d/b/a PMG Research of Cary
    Cary, North Carolina 27518, United States
  • PMG Research of Charlotte, LLC
    Charlotte, North Carolina 28209, United States
  • PMG Research of Hickory, LLC
    Hickory, North Carolina 28601, United States
  • PMG Research of Rocky Mount, LLC - Investigational Product and Mail delivery
    Rocky Mount, North Carolina 27804, United States
  • PMG Research of Rocky Mount, LLC - Patient Visits
    Rocky Mount, North Carolina 27804, United States
  • Carolina Research Center, Inc.
    Shelby, North Carolina 28150, United States
  • PMG Research of Winston-Salem, LLC
    Winston-Salem, North Carolina 27103, United States
  • Sterling Research Group, Ltd.
    Cincinnati, Ohio 45219, United States
  • Heritage Valley Medical Group, Inc.
    Beaver, Pennsylvania 15009, United States
  • Palmetto Clinical Research
    Summerville, South Carolina 29485, United States
  • Palmetto Primary Care Physicians (physicals only)
    Summerville, South Carolina 29485, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • Juno Research, LLC
    Houston, Texas 77074, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Bountiful Internal Medicine
    Bountiful, Utah 84010, United States
  • Progressive Clinical Research
    Bountiful, Utah 84010, United States
  • Wade Family Medicine
    Bountiful, Utah 84010, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Nov 2021, 10 months.

Results were first posted in Dec 2022, 1 year after primary completion.

Of 65 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 10 months is below that.

Counting every sponsor, half of 147 studies reached it within 27 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2020
First posted
Nov 5, 2020
StartActual
Jan 6, 2021
Primary completionActual
Nov 17, 2021
CompletionActual
Nov 17, 2021
Results first posted
Dec 8, 2022
Last update
Dec 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04617275
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 5, 2020
Start date
Jan 6, 2021
Primary completion
Nov 17, 2021
Completion
Nov 17, 2021
Results posted
Dec 8, 2022
Last update
Dec 8, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danuglipron

Start the discussion